New Drugs of 2010

Pharmacy Times Office of Continuing

Professional

Education The much-anticipated New Drugs CE is now available on PharmacyTimes.com!

This year, this important overview of the latest FDA approvals has been split into 2 activities to provide pharmacists with even more information about the latest molecular entities and biologic products.

New Drugs of 2010: Part 1

Michael Mancano, PharmD

New drugs were approved in 2010 for the treatment of a variety of conditions, including multiple sclerosis, stroke/systemic embolism, postmenopausal osteoporosis, and schizophrenia. Part 1 of this CE activity examines the indications, mechanisms of action, drug interactions, and dosing of 8 new molecular entities:

• Dabigatran etexilate mesylate capsules (Pradaxa)
• Dalfampridine extended-release tablets (Ampyra)
• Denosumab injection (Prolia, Xgeva)
• Estradiol valerate and estradiol valerate/dienogest (Natazia)
• Everolimus tablets (Zortress)
• Incobotulinumtoxina injection (Xeomin)
• Liraglutide rDNA injection (Victoza)
• Tocilizumab injection (Actemra)

Educational Objectives

Upon completion of this educational activity, participants should be able to:

1. Discuss the clinical indications of the new drugs approved by the FDA in 2010.

2. Explain the various mechanisms of action of the drugs discussed in this program.

3. Recognize the clinically relevant drug interactions for the drugs reviewed in this program.

4. Identify the most common adverse reactions for the new drugs of 2010.

5. Cite the approved dosing guidelines and recommended dosage adjustments for the drugs reviewed.

Credits: 2.0

Expiration date: January 24, 2013.

Click here to view this lesson.

New Drugs of 2010: Part 2

Michael Mancano, PharmD

Part 2 of this activity examines the indications, mechanisms of action, drug interactions, and dosing of 8 more molecular entities that were approved by the FDA in 2010:

• Alcaftadine ophthalmic solution (Lastacaft)
• Cabazitaxel injection (Jevtana)
• Ceftaroline fosamil injection (teflaro)
• Fingolimod capsules (Gilenya)
• Lurasidone HCl tablets (Latuda)
• Pegloticase injection (Krystexxa)
• Tesamorelin acetate injection (Egrifta)
• Ulipristal acetate tablets (Ella)

Educational Objectives

Upon completion of this educational activity, participants should be able to:

1. Discuss the clinical indications of the new drugs approved by the FDA in 2010.

2. Explain the various mechanisms of action of the drugs discussed in this program.

3. Recognize the clinically relevant drug interactions for the drugs reviewed in this program.

4. Identify the most common adverse reactions for the new drugs of 2010.

5. Cite the approved dosing guidelines and recommended dosage adjustments for the drugs reviewed.

Credits: 2.0

Expiration date: February 15, 2013.

Click here to view this lesson.

About the Pharmacy Times Office of Continuing Professional Education

The Pharmacy Times Office of CPE (PTOCPE) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The PTOCPE provides timely, high-quality, free continuing education in variety of formats, including print, live CE meetings, and online. To explore the full list of current CE offerings, click here.

The PTOCPE is now mobile as well! The Pharmacy CPE app helps keep busy pharmacists up-to-date on the latest continuing education lessons, Web exclusives, and highlights from the monthly publication. Pharmacy Times mobile also communicates directly with participants’ continuing professional education accounts, keeps track of credits earned, and sends reminders to print certificates after program completion. Download the Pharmacy CPE App from the iTunes Store today!

Mission

The mission of the PTOCPE is to:

• Enhance the knowledge, skills, and confidence of pharmacy professionals resulting in better patient care and an improved health care environment.
• Offer high quality, custom‐designed continuing education activities that are timely, relevant, and effective.
• Assist pharmacists and pharmacy technicians in meeting their continuing education requirements for license renewal.

For more information, please send an e-mail to ceinfo@pharmacytimes.com.